- Home
- BTBT vs SKYE Comparison
BTBT vs SKYE Comparison
Compare BTBT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBT
- SKYE
- Stock Information
- Founded
- BTBT 2015
- SKYE 2012
- Country
- BTBT United States
- SKYE United States
- Employees
- BTBT N/A
- SKYE N/A
- Industry
- BTBT Finance: Consumer Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- BTBT Finance
- SKYE Health Care
- Exchange
- BTBT Nasdaq
- SKYE Nasdaq
- Market Cap
- BTBT 467.0M
- SKYE 108.3M
- IPO Year
- BTBT 2018
- SKYE N/A
- Fundamental
- Price
- BTBT $4.13
- SKYE $4.78
- Analyst Decision
- BTBT Strong Buy
- SKYE Buy
- Analyst Count
- BTBT 2
- SKYE 6
- Target Price
- BTBT $6.50
- SKYE $18.67
- AVG Volume (30 Days)
- BTBT 8.3M
- SKYE 330.3K
- Earning Date
- BTBT 11-12-2024
- SKYE 11-09-2024
- Dividend Yield
- BTBT N/A
- SKYE N/A
- EPS Growth
- BTBT N/A
- SKYE N/A
- EPS
- BTBT 0.27
- SKYE N/A
- Revenue
- BTBT $86,851,522.00
- SKYE N/A
- Revenue This Year
- BTBT $192.83
- SKYE N/A
- Revenue Next Year
- BTBT $40.81
- SKYE N/A
- P/E Ratio
- BTBT $15.34
- SKYE N/A
- Revenue Growth
- BTBT 153.87
- SKYE N/A
- 52 Week Low
- BTBT $1.76
- SKYE $1.44
- 52 Week High
- BTBT $5.27
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- BTBT 69.21
- SKYE 53.92
- Support Level
- BTBT $2.91
- SKYE $3.53
- Resistance Level
- BTBT $3.52
- SKYE $4.53
- Average True Range (ATR)
- BTBT 0.24
- SKYE 0.41
- MACD
- BTBT 0.09
- SKYE 0.15
- Stochastic Oscillator
- BTBT 99.19
- SKYE 100.00
About BTBT Bit Digital Inc.
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries.. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. It generates revenue from digital asset mining and ETH staking business.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.